Non-biological complex drugs

Last updated

Non-biological Complex Drugs (NBCDs) are medical compounds that cannot be defined as small molecular, fully identifiable drugs with active pharmaceutical ingredients. They are highly complex and cannot be defined as biologicals as they are not derived from living materials. NBCDs are synthetic complex compounds and they contain non-homomolecular, closely related molecular structures with often nanoparticular properties. This is, for instance, the case with the iron sucrose and its similars. But also with other drug products, e.g. polypeptides (glatiramoids), swelling polymers, liposomes as the NBCD class is growing. [1] [2] [3] Hence and due to their complexity and specific composition mix, such colloidal iron carbohydrate drugs cannot be fully identified, characterized, quantitated and/or described by physiochemical means to define their pharmaceutical properties. Therefore, contradictory to the generic paradigm pathway, relying on a full pharmaceutical identity and sameness in vitro evaluation exercise, they need additional (biological, in vivo) evaluation with a reference product to assess comparability e.g. in tissue targeting in the body. This requires an appropriate, yet to be defined and be harmonized regulatory approach for these new class of medicinal products. [4] [5] The profile and the performance of NBCDs is defined by the multi-step manufacturing process, which is laborious, difficult to control and not disclosed by intellectual property. Minimal changes in for instance the starting materials or the process conditions might result in significant clinical differences affecting therapeutic effects or safety. [1] [3]

Contents

Clinical Data

Studies have shown differences in therapeutic and safety effects between originator NBCDs and approved similar, even though these compounds had shown high similarities in physicochemical character. The structures responsible for these therapeutic differences are unknown. The differences in efficiency and safety (in vivo profile) cannot be detected in in vitro testing, as it is impossible to isolate and fully characterize these compounds. Nor are there defined models for proper evaluation. [3] Furthermore, it is unknown what to look for and what causes the differences, due to a lack of understanding of the exact composition. This calls for additional characterization in biological systems including clinical head-to-head analysis to define the extent of similarity and the place in therapy as therapeutic alternatives or interchangeable/substitutable medicinal products. Clear evidence for these observations comes from retrospective studies on iron sucrose and iron sucrose similars. [6] [7] [8] [9]

Approval challenges for iron sucrose similars

NBCDs have been approved according to the classical generic paradigm based on pharmaceutical equivalence and bioequivalence without realizing the nano-properties of these type of medicinal compounds. Therefore, these compounds were seen as therapeutically equivalent. As mentioned above such an approach is not valid for follow-on versions of NBCDs. The classical generic approach disregards the complexity of NBCD compounds (pharmaceutical and biodistribution aspects) as they cannot be fully characterized in vitro, which is a prerequisite for the generic approach to predict pharmaceutical (quality) equivalence. [6] [10] The reason is the complexity and the non-homologous composition of these synthetic large molecular products. Even slight differences in manufacturing might result in therapeutic or safety differences not to be attributed to a known or defined component.

The existing and defined biosimilar pathway , taking into consideration the complexity of biologics and its follow-on products, is neither applicable for NBCDs and its similars. Since NBCDs are by definition not biologicals but are rather synthetic. However, basic principles can be used for an NBCD similar evaluation. [2] [6] [11] [12] Since the NBCD follow-on versions are not identical but only similar to the originator product, they are never the same as it is with generic small molecule products. NBCDs and their similars containing nanoparticulate can also be referred to as nanosimilars [3] (see figure 1). A stepwise quality, non-clinical and clinical approach is suggested for market approval of NBCD nanosimilars and to show comparability. There is a lack of non-clinical models to test such products like e.g. the rodent approach addressed by EMA in their reference paper for the NBCDs iron sucrose and its similars. [6] Recently, the hatching egg model was used as an alternative model to study time-dependent iron concentrations in heart and liver avian tissues for various intravenous iron complexes applied in equimolar doses. [13] Such models need in-depth evaluation and validation to demonstrate robustness and to further define potential use in an evaluation and comparison testing. [14] When evaluated similar enough, the challenge then still is to define to either use them as a therapeutic alternative or as an equivalent product and if at the end the follow-on version can substitute the reference product or can be interchanged which also needs head-to-head comparisons in patients to prove therapeutic equivalence and comparable safety.

Both the European Medicines Agency (EMA) and the US Food and Drug Administration (US FDA) have drafted reference papers and guidance’s for the industry for several types of NBCDs, e.g. for iron nanoparticles products. Also regulatory science initiatives have addressed lacking investigations. [6] [9] [13] [15] [16] [17] [18] [19] For the comparability exercise the question stays to evaluate the totality of evidence for enough similarity of such test drugs with the reference product to conclude of the extent of comparability and its impact on use. Currently, the FDA follows a case-by-case approach for the evaluation of NBCD follow-on products, which is iterative, adaptive and flexible but also more general. The EMA on the other hand is supporting a class-related approach including non-clinical testing. A harmonized approach is, however, still missing.

Related Research Articles

<span class="mw-page-title-main">Pharmacology</span> Branch of biology concerning drugs

Pharmacology is a science of medical drug and medication, including a substance's origin, composition, pharmacokinetics, therapeutic use, and toxicology. More specifically, it is the study of the interactions that occur between a living organism and chemicals that affect normal or abnormal biochemical function. If substances have medicinal properties, they are considered pharmaceuticals.

<span class="mw-page-title-main">Generic drug</span> Pharmaceutical equivalent to a brand-name product

A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active chemical substance is the same, the medical profile of generics is equivalent in performance compared to their performance at the time when they were patented drugs. A generic drug has the same active pharmaceutical ingredient (API) as the original, but it may differ in some characteristics such as the manufacturing process, formulation, excipients, color, taste, and packaging.

<span class="mw-page-title-main">Bioequivalence</span>

Bioequivalence is a term in pharmacokinetics used to assess the expected in vivo biological equivalence of two proprietary preparations of a drug. If two products are said to be bioequivalent it means that they would be expected to be, for all intents and purposes, the same.

<span class="mw-page-title-main">European Medicines Agency</span> Agency of the European Union

The European Medicines Agency (EMA) is an agency of the European Union (EU) in charge of the evaluation and supervision of pharmaceutical products. Prior to 2004, it was known as the European Agency for the Evaluation of Medicinal Products or European Medicines Evaluation Agency (EMEA).

A biopharmaceutical, also known as a biological medical product, or biologic, is any pharmaceutical drug product manufactured in, extracted from, or semisynthesized from biological sources. Different from totally synthesized pharmaceuticals, they include vaccines, whole blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living medicines used in cell therapy. Biologics can be composed of sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living cells or tissues. They are isolated from living sources—human, animal, plant, fungal, or microbial. They can be used in both human and animal medicine.

A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.

<span class="mw-page-title-main">Flupirtine</span> Non-opioid analgesic

Flupirtine is an aminopyridine that functions as a centrally acting non-opioid analgesic that was originally used as an analgesic for acute and chronic pain but in 2013 due to issues with liver toxicity, the European Medicines Agency restricted its use to acute pain, for no more than two weeks, and only for people who cannot use other painkillers. In March 2018, marketing authorisations for flupirtine were withdrawn following a European Medicines Agency recommendation based on the finding that the restrictions introduced in 2013 had not been sufficiently followed in clinical practice, and cases of serious liver injury still occurred including liver failure.

Safety pharmacology is a branch of pharmacology specialising in detecting and investigating potential undesirable pharmacodynamic effects of new chemical entities (NCEs) on physiological functions in relation to exposure in the therapeutic range and above.

The following outline is provided as an overview of and topical guide to clinical research:

<span class="mw-page-title-main">Remimazolam</span> Chemical compound

Remimazolam, sold under the brand name Byfavo, is a medication for the induction and maintenance of procedural sedation in adults for invasive diagnostic or surgical procedures lasting 30 minutes or less. It is a benzodiazepine drug, developed by PAION AG in collaboration with several regional licensees as an alternative to the short-acting imidazobenzodiazepine midazolam, for use in the induction of anesthesia and conscious sedation for minor invasive procedures. Remimazolam was found to have both a more rapid onset and a shorter duration than midazolam, and human clinical trials showed a faster recovery time and predictable, consistent pharmacokinetics, suggesting some advantages over existing drugs for these applications.

Evinacumab, sold under the brand name Evkeeza, is a monoclonal antibody medication for the treatment of homozygous familial hypercholesterolemia (HoFH).

<span class="mw-page-title-main">Difelikefalin</span> Chemical compound

Difelikefalin, sold under the brand name Korsuva, is an opioid peptide used for the treatment of moderate to severe itch. It acts as a peripherally-restricted, highly selective agonist of the κ-opioid receptor (KOR).

Eptinezumab, sold under the brand name Vyepti, is a medication used for the preventive treatment of migraine in adults. It is a monoclonal antibody that targets calcitonin gene-related peptides (CGRP) alpha and beta. It is administered by intravenous infusion.

<span class="mw-page-title-main">Rimegepant</span> Medication for acute migraine in adults

Rimegepant, sold under the brand name Nurtec ODT among others, is a medication used for the acute treatment of migraine with or without aura in adults and the prophylactic/ preventive treatment of episodic migraine in adults. It is taken by mouth to dissolve on or under the tongue. It works by blocking CGRP receptors.

<span class="mw-page-title-main">Casirivimab/imdevimab</span> Antiviral combination medication

Casirivimab/imdevimab, sold under the brand name REGEN‑COV among others, is a combination medicine used for the treatment and prevention of COVID‑19. It consists of two human monoclonal antibodies, casirivimab and imdevimab that must be mixed together and administered as an infusion or subcutaneous injection. The combination of two antibodies is intended to prevent mutational escape. It is also available as a co-formulated product. It was developed by the American biotechnology company Regeneron Pharmaceuticals.

<span class="mw-page-title-main">Sotrovimab</span> Monoclonal antibody

Sotrovimab, sold under the brand name Xevudy, is a human neutralizing monoclonal antibody with activity against severe acute respiratory syndrome coronavirus 2, known as SARS-CoV-2. It was developed by GlaxoSmithKline and Vir Biotechnology, Inc. Sotrovimab is designed to attach to the spike protein of SARS-CoV-2.

Amivantamab, sold under the brand name Rybrevant, is a bispecific monoclonal antibody used to treat non-small cell lung cancer. Amivantamab is a bispecific epidermal growth factor (EGF) receptor-directed and mesenchymal–epithelial transition (MET) receptor-directed antibody. It is the first treatment for adults with non-small cell lung cancer whose tumors have specific types of genetic mutations: epidermal growth factor receptor (EGFR) exon 20 insertion mutations.

Valoctocogene roxaparvovec, sold under the brand name Roctavian, is a gene therapy used for the treatment of hemophilia A. It was developed by BioMarin Pharmaceutical. Valoctocogene roxaparvovec is made of a virus (AAV5) that has been modified to contain the gene for factor VIII, which is lacking in people with hemophilia A. It is an adeno-associated virus vector-based gene therapy. It is given by intravenous infusion.

Avalglucosidase alfa, sold under the brand name Nexviazyme, is an enzyme replacement therapy medication used for the treatment of glycogen storage disease type II.

References

  1. 1 2 Crommelin, D. J., & de Vlieger, J. S. (2015). Epilogue: What Did We Learn? What Can We Expect in the Future? Concluding Remarks and Outstanding Issues. In Non-Biological Complex Drugs (pp. 381-388). Springer International Publishing.
  2. 1 2 Borchard, G., Flühmann, B., & Mühlebach, S. (2012). Nanoparticle iron medicinal products–Requirements for approval of intended copies of non-biological complex drugs (NBCD) and the importance of clinical comparative studies. Regulatory Toxicology and Pharmacology, 64(2), 324-328.
  3. 1 2 3 4 Crommelin D. J., de Vlieger J. S., Weinstein V., Mühlebach S., Shah V. P., Schellekens H. Different pharmaceutical products need similar terminology. AAPS J. 16, 11–14 (2014).
  4. ↑ Toblli, J. E., Cao, G., Oliveri, L., & Angerosa, M. (2012). Comparison of oxidative stress and inflammation induced by different intravenous iron sucrose similar preparations in a rat model. Inflammation & allergy drug targets, 11(1), 66.
  5. ↑ Toblli JE, Cao G, Oliveri L, Angerosa M. Differences between the original iron sucrose complex Venofer® and the iron sucrose similar Generis®, and potential implications. Port. J. Nephrol. Hypert. 23(1), 53–63 (2009).
  6. 1 2 3 4 5 GDUFA Regulatory Science. 2015. https://www.fda.gov/ForIndustry/UserFees/GenericDrugUserFees/ucm370952.htm
  7. ↑ Agüera, M. L., Martin-Malo, A., Alvarez-Lara, M. A., Garcia-Montemayor, V. E., Canton, P., Soriano, S., & Aljama, P. (2015). Efficiency of Original versus Generic Intravenous Iron Formulations in Patients on Haemodialysis. PLoS ONE, 10(8), e0135967.
  8. ↑ Stein, J., Dignass, A., & Chow, K. U. (2012). Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Current Medical Research & Opinion, 28(2), 241-243.
  9. 1 2 EMA CHMP/SWP. Draft reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product. www.ema.europa.eu
  10. ↑ Toblli, J. E., Cao, G., & Angerosa, M. (2015). Nitrosative stress and apoptosis in non-anemic healthy rats induced by intravenous iron sucrose similars versus iron sucrose originator. BioMetals, 28(2), 279-292.
  11. ↑ Schellekens H., Klinger E., Mühlebach S., Brin J., Storm G., Crommelin D. J. The therapeutic equivalence of complex drugs. Regul. Toxicol. Pharmacol. 59, 176–183 (2011).
  12. ↑ Mühlebach S., Vulto A., de Vlieger J. S. B., Weinstein V., Flühmann B., Shah V. P. The authorization of non-biological complex drugs (NBCDs) follow-on versions: specific regulatory and interchangeability rules ahead? GaBI J. 2(4), 1–4 (2013).
  13. 1 2 EMA CHMP/SWP/2015. Draft reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product. www.ema.europa.eu
  14. ↑ Spicher, K., Brendler-Schwaab, S., Schlösser, C., Catarinolo, M., Fütterer, S., Langguth, P., & Enzmann, H. (2015). Differences in tissue distribution of iron from various clinically used intravenous iron complexes in fetal avian heart and liver. Regulatory Toxicology and Pharmacology, 73(1), 65-72.
  15. ↑ EMA EMA/CHMP/SWP/100094/2011. Reflection paper on non-clinical studies for generic nanoparticle iron medicinal product applications. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2011/04/WC500105048.pdf
  16. ↑ EMA CHMP/SWP/620008/2012. Overview of comments received on Reflection paper on the data requirements for intravenous iron-based nano-colloidal products developed with reference to an innovator medicinal product.
  17. ↑ FDA Draft guidance on Iron Sucrose rev. http://www.fda.gov
  18. ↑ FDA. Guidance for industry considering whether an FDA-regulated product involves the application of nanotechnology. http://www.fda.gov
  19. ↑ FDA Guidance for Industry Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. http://www.fda.gov
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.